# Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

> **NCT01836705** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 60 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** SAR302503 (TG101348)
- **DRUG:** Placebo SAR302503
- **DRUG:** Panolosetron

## Key facts

- **NCT ID:** NCT01836705
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-11
- **Final completion:** 2014-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836705, "Effect of SAR302503 on ECG Activity in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01836705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*